[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370717-105":59,"doc-detail-370717-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","immuno-oncology-at-the-crossroads-confronting-challenges-in-the-quest-for-effective-cancer-therapies","Immuno-Oncology at the Crossroads - Confronting Challenges in the Quest for Effective Cancer Therapies","","Immuno-oncology has rapidly evolved into a cornerstone of modern cancer therapy, enabling durable responses and personalized treatment strategies. This narrative review synthesizes mechanisms driving tumor–immune system interactions and highlights therapeutic innovations, with emphasis on the tumor microenvironment (TME) as a complex immune-stromal ecosystem. It surveys cellular and molecular determinants of immune escape, major immunotherapeutic modalities, predictive biomarkers for patient stratification and resistance monitoring, and the role of the microbiome in modulating clinical efficacy. The review frames key challenges and translational opportunities.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immuno-oncology-at-the-crossroads-confronting-challenges-in-the-quest-for-effective-cancer-therapies/370717/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immuno-oncology-at-the-crossroads-confronting-challenges-in-the-quest-for-effective-cancer-therapies/370717.png","ImageObject",300,407,{"name":92,"@type":93},"Terk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the central focus of this narrative review?","Question",{"text":113,"@type":114},"The review centers on tumor–immune system interactions in immuno-oncology, with particular attention to the tumor microenvironment (TME) and how it influences therapeutic outcomes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which immunotherapeutic approaches are discussed?",{"text":118,"@type":114},"Immune checkpoint inhibitors, cancer vaccines, adoptive cell therapies such as CAR-T cells, and cytokine-based interventions are covered.",{"name":120,"@type":111,"acceptedAnswer":121},"How does the review address biomarkers and treatment management?",{"text":122,"@type":114},"It highlights the growing importance of predictive biomarkers for inpatient stratification, monitoring resistance, and managing immunotherapy-related toxicity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},370717,1790260440,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \nImmuno-Oncology at the Crossroads: Confronting Challenges in the Quest for Effective Cancer Therapies  \nClaudiu Natanael Roznovan 1, Luminia Gabriela Măruescu 1,2, * and Gratiela Gradisteanu Pircalabioru 1,2,3  \nAcademic Editor: Wioletta Olejarz  \nReceived: 30 May 2025  \nRevised: 21 June 2025  \nAccepted: 22 June 2025  \nPublished: 26 June 2025  \nCitation: Roznovan, C.N.; Măruescu, L.G.; Gradisteanu Pircalabioru, G. Immuno-Oncology atthe Crossroads:  \nConfronting Challenges in the Quest for Effective Cancer Therapies. Int. J. Mol. Sci. 2025, 26, 6177. [https://](https://)[ ](https://)[doi.org/10.3390/ijms26136177](doi.org/10.3390/ijms26136177)  \n[Copyright:](Copyright:) © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Botany and Microbiology, Faculty of Biology, University of Bucharest, 030018 Bucharest, Romania; claudiu-natanael.roznovan@s.unibuc.ro (C.N.R.); [gratiela.gradisteanu@icub.unibuc.ro](gratiela.gradisteanu@icub.unibuc.ro) (G.G.P.)  \n2 Research Institute of University of Bucharest, 050107 Bucharest, Romania  \n3 eBio-Hub Centre of Excellence in Bioengineering, National University of Science and Technology Politehnica Bucharest, 060042 Bucharest, Romania  \n* Correspondence: [luminita.marutescu@bio.unibuc.ro](luminita.marutescu@bio.unibuc.ro)  \nAbstract  \nImmuno-oncology has rapidly evolved into a cornerstone of modern cancer therapy, offering promising avenues for durable responses and personalized treatment strategies. This narrative review provides a thorough overview of the mechanisms underlying tumor– immune system interactions and the therapeutic innovations emerging from this knowledge. Central to this discussion is the tumor microenvironment (TME), a complex ecosystem of immune and stromal cells that supports tumor growth and shapes therapeutic outcomes. Key cellular and molecular factors within the TME are examined, along with diverse immune escape strategies. We further analyze the landscape of immunotherapeutic approaches, including immune checkpoint inhibitors, cancer vaccines, adoptive cell therapies such as CAR-T cells, and cytokine-based interventions. This review also addresses the increasing importance of predictive biomarkers in immuno-oncology, particularly inpatient stratification, monitoring resistance, and managing immunotherapy-related toxicity. Finally, we explore the emerging role of the microbiome as a modulator of immunotherapy efficacy, shedding light on host–microbe–immune interactions that may influence clinical outcomes. By integrating current biological insights with therapeutic innovation, this review outlines the challenges and opportunities ahead in immuno-oncology and emphasizes the need for translational research and cross-disciplinary collaboration to optimize cancer immunotherapy in the era of precision medicine.  \nKeywords: immuno-oncology; immunotherapy; immune checkpoint inhibitors; tumor microenvironment; tumor–immune interactions; microbiome; precision oncology; biomarkerguided treatment  \n1. Introduction  \nCancer remains a significant and persistent threat to global public health, with a rising incidence and significant mortality burden despite major advancements in therapeutic strategies [1,2] . Traditional modalities such as surgery, chemotherapy, and radiotherapy, although effective in certain localized tumors, often fall short in metastatic or resistant disease contexts [3,4] . The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs) and personalized cancer vaccines, has revolutionized oncologic treatment paradigms by leveraging the immune system’s mechanisms to recognize and destroy malignant cells [5–7] . However, the effectiveness of these strategies ","cbCaiimiM99BSPz8","https://ap.wps.com/l/cbCaiimiM99BSPz8","pdf",1482795,37,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What is the central focus of this narrative review?\",\"answer\":\"The review centers on tumor–immune system interactions in immuno-oncology, with particular attention to the tumor microenvironment (TME) and how it influences therapeutic outcomes.\"},{\"question\":\"Which immunotherapeutic approaches are discussed?\",\"answer\":\"Immune checkpoint inhibitors, cancer vaccines, adoptive cell therapies such as CAR-T cells, and cytokine-based interventions are covered.\"},{\"question\":\"How does the review address biomarkers and treatment management?\",\"answer\":\"It highlights the growing importance of predictive biomarkers for inpatient stratification, monitoring resistance, and managing immunotherapy-related toxicity.\"}]","Immuno-Oncology at the Crossroads - Confronting Challenges in the Quest for Effective Cancer Therapies | PDF",1790190051,93,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4fac05919adf75e007b0c9528c92aa6.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd6064cf3c4a32ae3a6eb136e2293b7b.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3da794dc3c28fef4484f746949f7336.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c72619833288092bd5231e442157090b.webp",980,1385]